June 10 2025
Biotecgen (Colombia) and OncoInv (The Netherlands) have joined forces to make multi-cancer early detection accessible in Colombia. Biotecgen will offer OncoSeek®, a patient-friendly solution for cancer detection, requiring only a blood sample to detect 9 types of cancer.
At OncoInv, we are proud to support forward-thinking partners who take bold steps in improving cancer detection. Biotecgen’s decision to partner with OncoInv and implement OncoSeek® is a powerful example of this commitment. Recognising the urgent need for early, accurate, and accessible detection in Latin America, Biotecgen chose OncoSeek® as a scientifically validated solution capable of identifying cancer at its most treatable stage.
This strategic move reflects a shared mission between Biotecgen and OncoInv: to democratise access to high-precision detection tools, reduce health inequalities, and ensure that innovation reaches even the most remote regions. Through this collaboration, Biotecgen joins a growing global network of institutions dedicated to changing the trajectory of cancer care.
OncoSeek® aligns perfectly with Biotecgen’s mission to lead, innovate, and create meaningful impact in patients’ lives. Their decision to work with Oncoseek® is both strategic and deeply consistent with their purpose: to transform healthcare through solutions that save lives.
A revolution in cancer diagnosis
OncoSeek® covers the most common aggressive cancers and its specificity and sensitivity are considered better than traditional approaches in the realm of early detection and diagnosis.
Blood samples are analysed on 6 Protein Tumour Markers (PTM). The resulting data is processed by the cloud-based OncoSeek® software using Machine Learning to analyse the resulting data sets. The algorithm is operated by OncoInv and is fully GDPR compliant.
OncoSeek® has been developed by SeekIn (China, US). SeekIn has partnered with OncoInv to make its products available to as many countries as possible. To fulfil this ambition OncoInv offers the products at low cost with an explicit focus on Low- and Middle-Income Countries.
About Biotecgen
Biotecgen is a leading Colombian company in health-focused genetics, specialized in genetic diagnostics, clinical, molecular testing, and precision medicine. With operations in multiple cities and a clear vision for international expansion, Biotecgen has built a solid infrastructure through certified laboratories, advanced technological platforms, and high-level academic partnerships.
Their growth model is driven by a strong commitment to scientific research and innovation. They consistently invest in the development of new diagnostic approaches and actively seek strategic allies to accelerate projects that transform access to and the quality of genetic healthcare in Latin America. Biotecgen's mission is deeply rooted in health equity, scientific education, and sustainable social impact.
For more information about Biotecgen, visit www.biotecgen.com.co.
About OncoInv
OncoInv is based in Houten, the Netherlands. The mission of OncoInv is to make multi-cancer early detection solutions available to as many people as possible, thus improving the outcome for patients and their families. OncoInv offers its products and services on a not-for-profit basis in Low- and Middle-Income countries to ensure high availability by minimizing the costs. OncoInv is a fully owned subsidiary of the non-profit foundation Inspire2Live. For more information, please continue your visit on www.oncoinv.org.
About SeekIn
SeekIn is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing -generation sequencing and Machine Learning. Since founded, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukaemia patients. With its proprietary technical advances, SeekIn has launched several research and clinical studies in collaboration with top-tier hospitals. SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com.
About Inspire2Live
Inspire2Live is an international patient advocacy organisation operating on an international level. We are on a mission to inspire and empower patients, researchers and clinicians to work together to prevent, treat and eliminate cancer. If we all believe that healthcare should be for the benefit of patients, then we should be part of the discussion and the decision process: When about us, not without us. We achieve our goals by connecting stakeholders in the medical industrial complex and organising congresses and discovery networks. These connections have led to many initiatives which are transforming the way research and healthcare work to become more patient-centric. We operate globally in full respect of local considerations. For more information, please visit www.inspire2live.org.
